stilbenes and Schizophrenia

Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ.. This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%).. In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.

Topics: Adult; Aged; Antioxidants; Blood Glucose; Cardiovascular Diseases; Cholesterol; Dietary Supplements; Double-Blind Method; Humans; Male; Middle Aged; Plant Extracts; Resveratrol; Risk Factors; Schizophrenia; Stilbenes; Triglycerides; Young Adult

Resveratrol, a caloric restriction mimetic, is a naturally occurring polyphenolic compound with antioxidant and anti-inflammatory properties. Oxidative stress has been implicated in the etiology of a number of neuropsychiatric disorders including generalized anxiety and schizophrenia. This study investigated the anxiolytic and antipsychotic potentials of resveratrol in murine models of anxiety and schizophrenia. Mice were pretreated with resveratrol (200 and 400 mg/kg) in 1% carboxymethyl cellulose for 14 days and subjected to behavioural tests on the 15th day. Anxiolytic activity of resveratrol was determined using the hole board and staircase tests while its anti-psychotic property was evaluated via apormorphine induced stereotypy and swim-induced grooming tests. Although resveratrol did not significantly reduce the mean number of head dips at doses used in the hole board test, it significantly (p < 0.01) decreased the mean episodes of rearing without significantly altering the total number of upward steps climbed in the staircase test. Resveratrol significantly (p < 0.05) reduced the mean climbing scores in the first ten minutes of the apormorphine induced stereotypic climbing and significantly decreased (p < 0.01) episodes and total duration of swim induced grooming in mice. Administration of resveratrol at doses used in this study produced anxiolysis and anti-psychotic effects in mice.

Topics: Animals; Antioxidants; Antipsychotic Agents; Anxiety; Apomorphine; Behavior, Animal; Caloric Restriction; Exploratory Behavior; Female; Grooming; Male; Mice; Resveratrol; Schizophrenia; Schizophrenic Psychology; Stereotyped Behavior; Stilbenes; Swimming

Topics: Adult; Bipolar Disorder; Catatonia; Female; Humans; Menstruation; Middle Aged; Schizophrenia; Stilbenes